Close Menu

Grants

Additional funding opportunities

Research Funding Opportunities

Tools to Find Funding

Grants Awarded for Health Sciences Research

Title Type $ Amount Activity Investigator Unitsort descending Sponsor Date
A Phase Ib/II Study of Leronlimab (PRO 140) Combined with Carboplatin in Patients with CCR5+ Metastatic Triple-Negative Breast Cancer (mTNBC) Contract $122,212.50 Clinical Trial Sima Ehsani Chimeh Cancer Center Division CytoDyn Inc. 10/2020
Phase 1 Study of VE800 and Nivolumab in Patients with Selected Types of Advanced or Metastatic Cancer Contract $323,394.75 Clinical Trial Hani Babiker Cancer Center Division Vedanta Biosciences, Inc. 05/2020
A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies Contract $277,281.00 Clinical Trial Abhijeet Kumar Cancer Center Division BeiGene, Ltd. 06/2022
A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib Contract $28,800.00 Clinical Trial Holly Pariury Cancer Center Division Public Health Institute 05/2022
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First- Line Treatment of BRCA Non-Mutated Advanced... Contract $100,897.00 Clinical Trial Setsuko Chambers Cancer Center Division GOG Foundation, Inc. 08/2020
INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer, a Phase II Randomized Multi-center Trial With and Without APX005M, an Anti-CD40 Agonist Contract $70,892.00 Clinical Trial Aaron Scott Cancer Center Division University of Texas Southwestern Medical Center 02/2022
COG NCTN Network Group Operations Center Contract $750,000.00 Clinical Trial Holly Pariury Cancer Center Division Children's Hospital of Philadelphia 10/2020
A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate-2 or High-Risk Primary or Secondary Myelofibrosis Contract $252,225.12 Clinical Trial Jeffrey Pu Cancer Center Division Sumitomo Dainippon Pharma Oncology 06/2022
An open label, Phase I dose-finding study of BI 765179 as monotherapy and in combination with ezabenlimab (BI 754091) in patients with advanced solid cancers Contract $723,609.00 Clinical Trial Aaron Scott Cancer Center Division Boehringer Ingelheim International GmbH (Germany) 07/2022
Children's Oncology Group NCORP Research Base Contract $750,000.00 Clinical Trial Holly Pariury Cancer Center Division Children's Hospital of Philadelphia 10/2020
Phase 1/1b Multicenter, Open-Label, First-in-Human Dose Escalation and Dose Expansion Study to Assess Safety and Tolerability of Orally Administered PMD-026 in Patients with Metastatic Breast Cancer w Contract $100,897.00 Clinical Trial Pavani Chalasani Cancer Center Division Phoenix Molecular Designs (Canada) 02/2020
A Pivotal Randomized, Open-label Study of Optune (TTFIELDS, 200khz) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma Contract $450,303.24 Clinical Trial Baldassarre Stea Cancer Center Division Novocure GmbH (SWITZERLAND) 06/2022
A Multicenter, Phase 1/2 Study of Selinexor in Combination with Backbone Treatments or Novel Therapies in Patients with Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) Contract $541,268.00 Clinical Trial Daniel Persky Cancer Center Division Karyopharm Therapeutics Inc. 05/2021
Keystroke: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA) Plus Stereotactic Re-Irradiation versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Carcinoma Contract $32,000.00 Clinical Trial Jared Robbins Cancer Center Division Radiation Therapy Oncology Group 04/2021
One Time EOY, Integrated BIQSFP AAML1031 - Echocardiogram Reports and Images Cooperative Agreement $1,200.00 Clinical Trial Holly Pariury Cancer Center Division Children's Hospital of Philadelphia 04/2021
A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations Contract $230,527.72 Clinical Trial Rachna Shroff Cancer Center Division Seagen Inc. 03/2021
A Phase 3 Randomized, Double-blind Trial of Trilaciclib versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer Contract $299,953.80 Clinical Trial Aaron Scott Cancer Center Division G1 Therapeutics 05/2021
Open-label, Randomized Phase II Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD1-refractory/relapsed, Unresectable Stage III or IV Melanoma Contract $485,781.00 Clinical Trial Montaser Shaheen Cancer Center Division BioNTech (Germany) 04/2021
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma Contract $1,354,476.50 Clinical Trial Alejandro Recio Boiles Cancer Center Division Mirati Therapeutics, Inc. 03/2021
ULTRA-V: Phase 2/3 Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) Compared to Ublituximab and Umbralisib (U2) in Subjects with C Contract $9,880.00 Clinical Trial Daniel Persky Cancer Center Division TG Therapeutics, Inc. 06/2022
Noncoding RNA Biomarkers for Noninvasive and Early Detection of Pancreatic Cancer Cooperative Agreement $64,679.91 Research Denise Roe Cancer Center Division Beckman Research Institute of The City of Hope 03/2020
A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in combination with Low Dose Cyclophosphamide and Pembrolizumab, in Subjects with Selected Advanced or... Contract $336,093.00 Clinical Trial Rachna Shroff Cancer Center Division IMV Inc. (Canada) 03/2021
A Phase 3, Randomized, Open-label Study to Evaluate the Safety and Efficacy of Pembrolizumab + Lenvatinib + Chemotherapy Induction Therapy Followed by Pembrolizumab + Lenvatinib Compared with… Contract $500.00 Clinical Trial Aaron Scott Cancer Center Division Merck Sharp & Dohme Corp. 02/2021
A Randomized, Phase 2 Study of Stereotactic Body Radiation Therapy (SBRT) in Combination with GC4711 in the Treatment of Unresectable or Borderline Resectable, Nonmetastatic Pancreatic Cancer Contract $239,544.80 Clinical Trial Uma Goyal Cancer Center Division Galera Therapeutics, LLC 05/2021
Prospective Single Arm Medical Food Study to Evaluate a Standardized Nonessential Amino Acid Restriction (NEAAR) Medical Food for the Dietary Management of Metastatic Colorectal Cancer Contract $99,034.20 Clinical Trial Aaron Scott Cancer Center Division Faeth Therapeutics, Inc. 05/2022

Pages